1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light

Anticoagulant Use In Spotlight As Approval Nears

 
• By Mandy Jackson

A letter in the New England Journal of Medicine suggests the death of one extension trial participant treated with t-PA may have been caused by lecanemab, but a response notes fatal intracerebral hemorrhages have been seen after t-PA in certain patients in the absence of anti-amyloid drugs.

CT scan of brain with red area ( Imaging for hemorrhagic stroke or Ischemic stroke ( infarction ) concept )
Lethal brain hemorrhage has been observed in three lecanemab trial participants, including one who received placebo • Source: Shutterstock

Eisai Co., Ltd. and Biogen, Inc. should hear from the US Food and Drug Administration any day now whether the agency will grant accelerated approval for the amyloid protofibril-targeting antibody lecanemab, but one issue looming large over the treatment for early Alzheimer’s disease is how safe it will be for frail, elderly patients – particularly for individuals taking anticoagulants for cardiovascular disease or treated in the emergency room for a stroke. A new case study looking at one lecanemab clinical trial participant who died following anticoagulant use attempts to shed some light on the safety concern.

The New England Journal of Medicine (NEJM) published the case study on 4 January in a letter written by Nicholas...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.